PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	ANSMITTAL LETTER TO THE UNITED STATES	ATTORNEY'S DOCKET NUMBER PC25819A						
	DESIGNATED/ELECTED OFFICE (DO/EO/US) ICERNING A SUBMISSION UNDER 35 U.S.C. 371	U.S. APPLICATION (If known, ee 67 CFR 1.5)						
	TIONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
INTERNA	PCT/IB2005/000733 03/21/2005	03/26/2004						
TITLE OF INVENTION USE OF A SERINE PLAMYITOYLTRANSFERSE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA								
TEPERATURE PLANTITOTETRANSPERSE (SFT) INHIBITOR TO TREAT ATHEROSCIEROSIS AND DISCIPIDENIA								
HOMAN, REYNOLD, et al								
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:								
1. X	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.							
2. 📙 .	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.							
3. 📙 -	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.							
4. X	The US has been elected (Article 31).							
5. X	A copy of the International Application as filed (35 U.S.C. 371(c)(2))							
	a. x is attached hereto (required only if not communicated by the International Bureau).							
	b. has been communicated by the International Bureau.							
· 	c. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).							
	a. is attached hereto.							
_	b. has been previously submitted under 35 U.S.C. 154(d)(4).							
7.	Amendments to the claims of the International Application under PCT Article 19	(35 U.S.C. 371(c)(3))						
	a. are attached hereto (required only if not communicated by the International Bureau).							
	b. have been communicated by the International Bureau.							
	c. have not been made; however, the time limit for making such amendments has NOT expired.							
_	d. have not been made and will not be made.							
8. 🔲	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).							
9. X	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).							
10.	An English language translation of the annexes of the International Preliminary E Article 36 (35 U.S.C. 371(c)(5)).	xamination Report under PCT						
Items 11 to 20 below concern document(s) or information included:								
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12.	An assignment document for recording. A separate cover sheet in compliance with	th 37 CFR 3.28 and 3.31 is included.						
13.	A preliminary amendment.							
14. X	An Application Data Sheet under 37 CFR 1.76.							
15.	A substitute specification.	.						
16.	A power of attorney and/or change of address letter.							
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 1	13ter.2 and 37 CFR 1.821- 1.825.						
18.	A second copy of the published International Application under 35 U.S.C. 154(d)	(4).						
19. 🔲	A second copy of the English language translation of the international application	under 35 U.S.C. 154(d)(4).						

This collection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the completed form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

IAPS Rec'd PCT/PTO 26 SEP 2005

PTO-1390 (Rev. 07-2005)
Approved for use through 3/31/2007. OMB 0651-0021
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)			INTERNATIONAL APP	INTERNATIONAL APPLICATION NO.		ATTORNEY'S DOCKET NUMBER			
	0.0	0-1-7-1	PCT/IB2005/	000733	PC2581	9A			
20. Other items or information:									
Copy of t	Copy of the International Preliminary Report on Patentability								
	Copy of the PCT International Search Report								
Copy of the published PCT Application, WO 2005/092325 and a copy of Written Opinion of the International Searching Authority									
The following fees have been submitted				CALCULATIONS	PTO USE ONLY				
21. X Basic na	tional fee (37	CFR 1.492(a))		\$300	\$ 300.00				
22. x Examina	ion fee (37 Cl								
If the written opinion by IPEA/US i All other situations	ndicates all cl	\$ 200.00							
If the written opinion IPEA/US indi	cates all claim	\$ 500.00							
Search fee (37 CFR International International Search previously con All other situations	Searching Au Report prepar nmunicated to	000.00							
TOTAL OF 21, 22 and 23 =					\$1,000.00				
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing in compliance with 37 CFR 1.821(c) or (e) or computer program listing in an electronic medium) (37 CFR 1.492(j)). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.									
		Number of each additional 50 or fraction RATE thereof (round up to a whole number)			·				
54 - 100 =	54 - 100 = 0 /50 =			x \$250	\$ ·	•			
Surcharge of \$130.00 after the date of com		\$							
CLAIMS NUMBER FILED		NUMBER EXTRA	RATE	\$					
Total claims	15	- 20 =	0	x \$50	\$ \$0.00				
Independent claims 11		-3=	8	× \$200	\$ 1,600.00	·			
MULTIPLE DEPEND	ENT CLAIM(S	\$ 360.00							
		\$ 1,960.00							
Applicant claims	small entity st	,							
SUBTOTAL =					\$ 2,960.00				
Processing fee of \$130.00 for furnishing the English translation later than 30 months from the earliest claimed priority date (37 CFR 1.492(i)).					\$				
TOTAL NATIONAL FEE =					\$ 2,960.00				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					\$				
•		\$ 2,960.00							
					Amount to be refunded:	\$			
					Amount to be charged	\$			

IAP5 Rec'd PCT/PTO 26 SEP 2006

10/594348

PTO-1390 (Rev. 07-2005)

Approved for use through 3/31/2007. OMB 0651-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE s are required to respond to a collection of information unless it displays a valid OMB control number.

A check in the amount of \$ to cover the above fees is enclosed. 2,960.00 to cover the above fees. Please charge my Deposit Account No. 23-0455 in the amount of \$ _ A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0455 ___. A duplicate copy of this sheet is enclosed. c. 🔽 Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: SIGNATURE Steven R. Eck Pfizer, Inc. Steven R. Eck 2800 Plymouth Road NAME 36,126 Ann Arbor, MI 48105 Tel. (734) 622-4040 REGISTRATION NUMBER Fax (734) 622-1553

18									
. Group Art									
Invention: USE OF A SERINE PLAMYITOYLTRANSFERSE (SPT) INHIBITOR TO TREAT ATHEROSCLEROSIS AND DYSLIPIDEMIA									
·									
(Identify type of correspondence)									
1450									
(te)									

Note: Each paper must have its own certificate of mailing